Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01274182 · ClinicalTrials.gov registry record · Phase 1
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
A Phase 1 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 1
- Development phase
- 312
- Enrollment target
NCT01274182 is a Phase 1 study that has completed, run by Sandoz. The registered enrollment target is 312 participants.
The verdict
NCT01274182, a Phase 1 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 312 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.
Interventions
- BIOLOGICAL Rituxan
- BIOLOGICAL GP2013
- BIOLOGICAL MabThera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2011-01 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01274182
The ClinicalTrials.gov registry entry for NCT01274182 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituxan is the first listed.
NCT01274182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01274182 about?
NCT01274182 is a clinical study titled "GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy". The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.
What is the current status of trial NCT01274182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 312 participants. The study started on 2011-01. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01274182?
The interventions under investigation include: Rituxan (BIOLOGICAL), GP2013 (BIOLOGICAL), MabThera (BIOLOGICAL).
Who is sponsoring clinical trial NCT01274182?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.